Please assess the completion status of the following clinical trial:

Trial Title: Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of NPC~* Age \> 18 years old~* Measurable metastatic or recurrent disease (s)~* Received one prior chemotherapy regimen for metastatic or recurrent NPC which relapsed or became refractory before entry.~* ECOG PS 0, 1 or 2~* WBC \> 3,500/uL and ANC \> 1,500/uL Platelet \> 100,000/uL Creatinine - within normal limits SGOT \< 3 X UNL Bilirubin \< 2.0 mg/dL~* Ejection fraction \> 45% and no history of myocardial infarction or congestive heart failure in the last 6 months. No history of cardiac ventricular arrythmia or ventricle tachycardia, or uncontrolled atrial fibrillation or supraventricular tachycardia with hemodynamic compromising status.~* Random blood glucose level \< 250 mg~* Signed informed consent~Exclusion Criteria:~* Received more than one prior chemotherapy for metastatic or recurrent disease~* Ejection fraction \< 45%~* WBC \< 3,500/UL or ANC \< 1,500/UL or P/t \< 100,000/UL or SCOT\> 3 x UNL or Bilirubin \> 2.0 mg/dL or Creatinine \> UNL~* ECOG PS \> 3~* Hx of myocardial infarction within last 6 months~* Random blood glucose level less than or equal 250 mg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ifosfamide and Doxorubicin (Type: EXPERIMENTAL): Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma

Based on this trial design, predict the completion outcome and termination type (if applicable).